Schizophrenia …

Rebekah Jakel MD PhD

Neurobehavioral & Cognitive Disorders

Updated 03.07.2024
Released 12.28.2005
Expires For CME 03.07.2027

Schizophrenia

Author: Rebekah Jakel MD PhD

See Contributor Disclosures

Editor: Victor W Mark MD

Schizophrenia

In This Article

Quick Link

Introduction

Overview

Schizophrenia is a serious and persistent mental illness that has instilled fear, curiosity, and reverence through the ages. This complex condition affects an individual’s grasp on reality, which can severely limit the ability to live and work independently. The impact of schizophrenia extends beyond the individual to families and communities. Schizophrenia is associated with increased morbidity and mortality, and significant health care costs and resource utilization. The term “schizophrenia” likely encompasses a syndrome with various symptoms and signs that share a common feature of impairment in reality testing. Current research aims to identify mechanisms to explain the diverse phenotypes observed and to identify and understand possible subtypes. Alterations in the mesolimbic dopaminergic pathways as well as changes in the prefrontal cortex are thought to play a role in pathology. Pharmacological treatments targeting these pathways are the primary interventions; however, psychosocial treatments can effectively improve function and quality of life. Advances in neurobiology, brain imaging, and genetics have given us a window of understanding into the complexity of schizophrenia. This article aims to provide an overview of current research into this complex condition.

Key points

	• Schizophrenia is a heterogeneous clinical syndrome and likely a group of related conditions that share a common set of symptoms involving psychosis and compromised cognition.
	• The etiology of schizophrenia is complex and involves genetic, neurodevelopmental, environmental, and psychological triggers.
	• Although positive symptoms such as hallucinations and delusions are most commonly discussed, negative symptoms are equally or potentially more impairing.

Historical note and terminology

Depictions of schizophrenia have been found as far back as the second millennium B.C. Ancient texts from Greek and Roman literature, in addition to the Egyptian “Book of Hearts,” describe thought disturbances pathognomonic of schizophrenia in the ancient world.

Due to the lack of understanding of mental illness, patients with schizophrenia have often been mistreated. It wasn’t until the end of the 18th century that the French physician Philippe Pinel identified individuals with schizophrenia as “mentally ill” and in need of medical care. Still, psychopharmacological treatment was not introduced for another 150 years.

German psychiatrist Emil Kraeplin provided one of the first characterizations of the symptoms, course, and prognosis of schizophrenia in the late 1800s. He coined the term “dementia praecox,” emphasizing the cognitive deficits that occur in the early adolescence of patients with schizophrenia. This term was replaced in 1911, when Swiss psychiatrist Eugen Bleuler introduced the term “schizophrenia,” stressing the occurrence of schisms among thought, emotion, and behavior. Although often used in lay vernacular, “schizophrenia” is not synonymous with multiple personality disorder or split personality.

Clinical manifestations

Presentation and course

Schizophrenia belongs to a larger group of psychotic disorders that are characterized by disturbances in cognition, perception, flow and organization of thought, and motor behavior. No single specific symptom is pathognomonic of the condition. The diagnosis of schizophrenia is made based on criteria defined in the DSM-5 (Table 1) and requires symptoms to have occurred for 6 months or longer. In contrast, brief psychotic disorder is defined by psychotic symptoms that are present for at least a day and up to a month. Symptoms that persist for at least a month, but not more than 6 months, are defined as schizophreniform disorder.

Table 1. Diagnostic Criteria for Schizophrenia, as defined by the Diagnostic and Statistical Manual of Mental Disorders, 5th edition

	1. Two or more during a significant part of a month. At least one symptom must be either delusions, hallucinations, or disorganized speech.
		a. Delusions b. Hallucinations c. Disorganized speech d. Disorganized behavior or catatonia e. Negative symptoms
	2. Impaired function in work, relationships, or self-care.
	3. Disturbances greater than 6 months with at least 1 month of active symptoms but may include prodrome or residual symptoms.
	4. Other psychotic disorders, medications, or medical conditions have been ruled out.
	5. A diagnosis of schizophrenia can be given to individuals with a prior history of autism or communication disorder if they have prominent hallucinations or delusions and meet the other criteria.
Adapted from (01)

Features are typically divided into “positive” and “negative’ symptoms. Positive symptoms are those that are absent in health, such as hallucinations and delusions. Negative symptoms are lacking or disrupted in disease but present in health and include changes in executive function, working memory, and attention.

Positive symptoms. Delusions are fixed, false beliefs that remain firm despite overwhelming proof in dispute. Delusional beliefs are outside the bounds of culture, such that religious beliefs held by a group of believers are not conceptually delusional. Delusions can vary in their themes, valence, and degree of implausibility (see Table 2).

Table 2. Common Types of Delusions

Delusion	Definition	Example
Persecutory or paranoid	Belief that one is being targeted, tracked, or harmed by another person, group, or agent	Bizarre: “Aliens are putting implants into my knees and tracking my behavior to slowly kill me.” Non-bizarre: “The FBI has surveillance on me and is tracking my every move.”
Somatic	Belief regarding organ function or health	Bizarre: “My body is being eaten alive by demons.” Non-bizarre: pseudocyesis (false pregnancy)
Grandiose	Belief that individual has exceptional abilities or importance	Bizarre: “I am the Devil.” Non-bizarre: “I’m a famous doctor who has cured a lot of disease.”
Nihilistic	Belief that a major catastrophe will occur	Bizarre: “The world is going to end when the sun collides with the moon.” Non-bizarre: “I’m going to die in a car accident when I turn 30.”
Referential	Beliefs that certain environmental cues, situation, sounds, etc. are meant for or directed towards the individual	Typically bizarre: “The radiator is telling me to get a lottery ticket.”
Control or passivity	Belief in the loss of control of thoughts or manipulations by an external force	Typically bizarre. Thought withdrawal: “Someone is taking thoughts out of my head.” Thought insertion: “Someone is putting thoughts in my head.”
Erotomanic	False belief that another person is in love with them.	Bizarre: “Elvis is in love with me.” Non-bizarre: “The plumber is in love with me.”

Hallucinations are perceptual experiences that occur without an external stimulus. Hallucinations can occur in any sensory modality (auditory, visual, tactile, olfactory, or gustatory). In schizophrenia, hallucinations are primarily auditory in nature as one or more voices that may or may not be familiar and are distinct from the individual’s thoughts. Classic descriptions of auditory hallucinations include a running commentary of multiple voices that are often derogatory in their content.

Other features of schizophrenia include disorganization of speech, which is believed to demonstrate disorganization of thought; hence, schizophrenia is designated as a “formal thought disorder” (Table 3).

Table 3. Features of Disorganization Noted in Speech in Schizophrenia

Feature	Definition	Example
Loosening of association or derailment	Spontaneous speech characterized by ideas jumping from one topic to another with minimal to no relationship between topics to sound disjointed.	“My favorite flower is a rose. They prick the finger for an accucheck. Like a map of a road, the path is there.”
Incoherence (word salad)	Speech abnormality at the level of the clause such that words and phrases are joined in an unclear, incomprehensible manner.	“I was a school, eating cereal at lunch. It’s rice in the air, but the time was thick and red and they brought money too, so I was questions hungry, and that is deep. Oceans to you, that is pop, a balloon.”
Clanging	Speech that connects words based on their sound rather than meaning; punning can also occur.	“Is that your ring, ring, ring? It could wring a neck and sing ding ding a bling the ring bling bling.”

Disorganization can also be seen in motor behavior. Movements can be stereotyped (saluting, gestures) or nonspecific such as agitation, pacing, and childlike silliness. Catatonia is a complicated condition that is not specific to schizophrenia but can be associated with it. In this manifestation, patients show reduced or oppositional responses to environmental cues with motor symptoms that may include stereotypies, waxy flexibility, mutism, or stupor. (For more information, please see the Medlink article “Catatonia.”)

Negative symptoms. Much of the disability associated with schizophrenia can be attributed to negative symptoms, which are more prominent in schizophrenia than in other psychotic disorders. Negative signs and symptoms may include reduction or flattening of affect, decreased experience of pleasure (anhedonia), decreased motivation (avolition), and social withdrawal (asociality). The quality of speech can become more impoverished with decreased speech (alogia) and changes in prosody. Cognitive changes can be apparent and can include poor concentration, impaired working memory, and changes in executive function.

Course of illness. The signs and symptoms used to define schizophrenia are typically first observed in late adolescence/early adulthood, although the pathologic processes underlying the condition likely precede the clinical onset. Frequently, patients with schizophrenia first come to psychiatric care during an active phase of symptoms. However, observable changes in behavior often precede the active phase by several months, a phase known as the “prodrome” (62; see Table 4). Of those who present with prodromal symptoms, the conversion rate to schizophrenia is 35%. Seventy percent of individuals achieve full remission within 3 to 4 months, and 80% achieve stable remission in 1 year.

Table 4. Prodrome of Schizophrenia

	Attenuated positive symptoms:
		• Unusual perceptions • Vague and circumstantial speech • Preoccupation with religion, occult, and philosophy • Suspiciousness • Anxiety • Praecox feeling: feeling by the clinician that the patient is “odd”
	Negative symptoms:
		• Blunted effect • Reduced motivation • Isolation and social withdrawal
	Cognitive symptoms:
		• Worsened academic, work, or social functioning, and self-care • Reduced attention and concentration
	General symptoms:
		• Sleep disturbances such as initial insomnia • Depressed mood • Irritable mood • Poor hygiene
Adapted from (46)

An initial psychotic episode may be acute, lasting only a few days or weeks but may progress over years, the latter being a negative prognostic feature. Several longitudinal courses of the illness can be differentiated: continuous, episodic with remission, episodic with stable deficit, episodic with progressive deficit, complete remission, incomplete remission, course uncertain, or period of observation too short (ie, the course should not be stated unless there has been a period of observation for at least 1 year).

In most cases, nonspecific prodromal symptoms, such as concentration deficits, agitation, insomnia, anxiety, anhedonia, anergia, and social withdrawal, will be reported by the patient or his/her relatives. Presentation largely depends on which dimension of thought, behavior, or affect is predominantly affected. Better prognosis may be associated with acute onset, older age at onset, clarity in presenting symptoms, more positive than negative symptoms, identifiable and treatable triggers, social support, insight to disorder, and medication compliance.

Given the variety of symptoms that can be seen in schizophrenia, there has been some effort to delineate clinical subtypes. The assumption is that different symptom clusters can be differentiated and will have differential prognoses and different treatment responses. Understanding the subtype could then guide and predict treatment and be an explanation for the variability in the existing data. Indeed, several subtypes of schizophrenia were defined in DSM-IV and earlier editions, including paranoid, catatonic, simple, residual, and undifferentiated schizophrenia. However, there haven’t been enough data to support these clinical subtypes and the most recent edition of the DSM does not include subtypes, despite the hope that symptom clusters and subtypes may have utility in guiding pharmacologic treatment or understanding the etiology with further research.

Prognosis and complications

The course of schizophrenia can vary substantially and is difficult to predict. Some patients may suffer one or two psychotic episodes and never again relapse while adhering to medication, whereas others may be able to discontinue medication carefully without suffering a relapse. About 20% of individuals with schizophrenia will have a favorable course, and a subset of these seem to recover to premorbid state. However, the majority have a chronic, relapsing, remitting illness with progressive worsening of negative symptoms and relative reduction of positive symptoms with age. A proportion of these are chronically and severely impaired, requiring significant support at baseline. Patients who demonstrate significant grandiosity and less severe hallucinations may be more likely to relapse (47).

Suicidality. The most dangerous complication of schizophrenia may be an elevated risk for suicide. In a 1-year follow-up study of first-episode psychosis, 11% of individuals attempted suicide, with hallucinations and a history of prior suicide attempts being the strongest predictors of suicidal behavior (42). Other studies suggest that depressive symptoms are the strongest predictor of suicidal behavior in schizophrenia. Additional clinical features that increase suicidal risk are prior attempts of suicide, severity of psychotic symptoms (particularly hallucinations and thought insertion), panic attacks and other anxiety symptoms, poor treatment adherence, repeated brief hospitalizations, high premorbid intelligence, and early stage of the illness (53). A meta-analysis of observational studies revealed a pooled lifetime prevalence of suicide attempts as high as 26.8% (36). Risk factors included earlier age of onset and living in a higher-income country. In a longitudinal study starting at first episode, protective factors included employment and longer period of untreated illness. Substance use significantly increased the risk of suicide (51).

Alcohol use is a modifiable risk factor that increases the risk of suicide in schizophrenia. Alcohol use was associated with completed and attempted suicide as well as suicidal ideation in a meta-analysis of schizophrenia (40).

Suicidality may be associated with abnormal brain structure and connectivity in fronto-temporo-limbic regions. Subcortical structures, such as the amygdala, play an important role in emotion regulation, aggression, and impulse control. Right amygdala hypertrophy, found on structural MRI, was found to be a risk factor for suicide attempts and self-aggression in a cross-sectional case-control study of patients with schizophrenia (50).

Aggression and violence. Violence in people with schizophrenia is uncommon. However, paranoia and command hallucinations may precipitate aggression in individuals with schizophrenia, elevating risk above the general population. Prevalence of recent aggression among outpatients with schizophrenia is around 5%. The types of violence and aggression are classified as follows: verbal aggression (around 45%), physical violence towards objects (around 30%), violence towards others (around 20%), and self-directed violence (around 10%). Family members are involved in 50% of the assaults; strangers are attacked in 20% of cases. Assessing acute risk of harm to self or others is a necessary challenge for mental health providers.

Homelessness. Schizophrenia is a significant contributor to disability worldwide. Large studies of homeless populations have revealed that psychotic disorders, including schizophrenia, are overrepresented as compared to domiciled individuals. This was higher in developing countries, up to 22% (03).

Clinical vignette

Mr. R is a 22-year-old man who presented with a 7-month history of social withdrawal, eventually ceasing to attend his university lectures. Members of his household became worried when he put tin foil on his windows to stop what he described as “others hearing my thoughts.”

The month prior to admission, Mr. R became convinced that the government was conspiring to “get rid” of him. He says he realized this when he saw a girl with red hair and a red coat looking at him on the bus 2 months prior to referral to psychiatric services. He also felt the government could control his moods and, at times, his left arm. He was convinced this was because the government wanted to get rid of all students to avoid paying for their studies and, ultimately, to avoid being challenged by intellectuals. He heard voices of two male government officials for 6 weeks prior to referral, but he could not see anyone around when he heard them. The voices talked about him between themselves and made critical comments about him. He denied depression or suicidal or homicidal ideation.

Mr. R had no significant medical history. Developmental history was unremarkable. He had used cannabis occasionally in his teenage years, although not recently. He had a family history of an uncle who was “eccentric, with odd ideas about things” and talked to himself, but the uncle had no specific psychiatric diagnosis.

Examination was remarkable for a malodorous young male with a disheveled appearance, wearing sunglasses and a hat lined with tinfoil in the office. He demonstrated affective blunting, poor eye contact, and hand wringing. Laboratory and imaging studies were all within normal limits.

He was diagnosed with schizophrenia due to a greater than 6-month history of prodromal symptoms, including a month of active phase symptoms with delusions, hallucinations, and social withdrawal that impaired function. Presentation could not be explained by another mental disorder, substance, or medical condition.

He was started on olanzapine 5 mg, which was eventually increased to 10 mg, and he was monitored by the community psychiatric team. He responded well to the olanzapine, and his presenting symptoms remitted in a few weeks. However, he became distressed by weight gain and discontinued the medication and disengaged from community support. This, unfortunately, led to a relapse of symptoms and hospitalization.

In the hospital, he was started on aripiprazole, with the hope that this medication would have less impact on his weight, and he was given cognitive behavior therapy to help him understand and make sense of his delusions and hallucinations when his mental state improved. Staff thoroughly explained the purpose and importance of medication. He was given diet and exercise advice and appropriate psychosocial support in the community. He subsequently returned to college.

Biological basis

Etiology and pathogenesis

It is generally agreed that schizophrenia is a multifactorial illness involving genetic and environmental interactions that result in alterations in synaptic plasticity, dendritic spine density, and synaptic transmission. Genetic vulnerability is shared in part with bipolar disorder, as well as developmental disorders such as autism (56). Table 5 describes the most commonly recognized risk factors for developing schizophrenia.

Table 5. The Common Risk Factors for Schizophrenia

Genetic risk factors
	• Having a relative suffer from schizophrenia may be the most important risk factor in developing the illness. The risk to develop schizophrenia for the general population is 0.5% to 1%. The first-degree relatives of a patient with schizophrenia have a risk of around 10%, and the offspring of two affected parents rises to 46%.
	• No specific single gene mutation can account for the disease. Various genes have been linked in the etiology of schizophrenia including the neuregulin 1 gene on chromosome 8, dysbindin gene on chromosome 8, and chromosome 22q11 (velocardiofacial syndrome).
Antenatal and perinatal risk factors
	• Second-trimester exposure to influenza infection may increase the risk of the fetus subsequently developing schizophrenia. Associations have also been found with maternal measles and rubella infections.
	• There is a significant association between schizophrenia and premature rupture of membranes, preterm labor, low birth weight, and use of resuscitation during delivery.
	• Fetal hypoxia during delivery predicts reduced grey matter throughout the cortex in people with schizophrenia, but not in controls.
	• Dizygotic twins have a higher concordance than non-twin siblings (with same genetic relatedness), suggesting a role of shared intrauterine environment.
Biological risk factors
	• Head injury
	• Epilepsy and temporal lobe disease
	• Substance use: Cannabis may increase the risk of schizophrenia in people who are homozygous for VAL/VAL alleles in COMT genotypes.
	• Arthritis: Patients suffering from rheumatoid arthritis have a lower risk to develop schizophrenia (one third the risk of the general population).
Demographic risk factors
	• Age and gender: Male patients with schizophrenia tend to have more severe disease with earlier onset, more structural brain disease, and worse premorbid adjustment as compared to female patients. Advanced paternal age at the time of birth is a risk factor for the offspring to develop schizophrenia.
	• Social class: It is still controversial whether a low social class is a result or contributor to the development of schizophrenia.
		1. “Breeder” hypothesis: socio-economic adversity precipitates schizophrenia in genetically vulnerable individuals.
		2. Social drift explanation: people who have an underlying predisposition to schizophrenia are more likely to drift down the social scale.
		3. Rural/urban difference: The higher prevalence of schizophrenia in urban areas is due to an interaction of genetic factors, migration, higher rates of social deprivation, and more social problems in the inner city. There is more favorable outcome in non-industrialized countries as compared to industrialized countries.
		4. Ethnicity: Afro-Caribbean immigrants to the United Kingdom have a higher risk of schizophrenia, even in the second generation.
Psychological risk factors
	• Stressful life events often precipitate the first psychotic episode.
	• High expressed emotion comprising of overinvolvement, critical comments, and hostility from family members for more than 35 hours per week is associated with risk of relapse of schizophrenia.

Although the population risk is around 1%, Gottesman’s twin and family studies demonstrate that the degree of risk correlates highly with the genetic relatedness (17). The highest risk of schizophrenia is in the offspring of two parents with schizophrenia (46%) and in monozygotic twins (48%) as compared to dizygotic twins (17%). Because dizygotic twins have almost double the risk of non-twin siblings, but on average similar genetic relatedness as non-twin siblings, shared early environment also affects risk.

The etiology of schizophrenia is complex and currently lacks a unifying mechanism to account for the signs and symptoms that are used to define the condition. Information to understand the pathogenesis has been derived from observational and heritability studies, functional imaging, and animal models.

Despite evidence for heritability, intensive genetic investigations have not identified a single “schizophrenia gene.” Rather, polymorphisms of certain genes seem to influence the susceptibility for the illness. Promising candidate genes include dysbindin, neuregulin, G72 (DAOA), the COMT gene, and others. Most of these polymorphisms have functional effects on brain maturation, synaptic transmission, and plasticity, and they probably lead to alternations in neurodevelopment (19).

Biological and morphological findings in patients with schizophrenia include widespread alterations in multiple regions, including the limbic system, frontal cortex, temporal lobe, and basal ganglia. A meta-analysis of cortical thickness throughout the whole brain in patients with schizophrenia, from first episode to chronic schizophrenia, as compared to healthy controls demonstrated reduced cortical thickness only in chronic schizophrenia in the right inferior frontal gyrus, bilateral insula, and superior temporal gyrus (52).

Reduced functional connectivity between different brain areas has been found as measured by fMRI (32). Global and regional white matter volumes in the prefrontal cortex (61) and prefrontal cortex cerebral blood flow as measured by fMRI have been shown to be reduced (20), referred to as hypofrontality. Several PET and SPECT studies have shown a pronounced increase of amphetamine-induced dopamine release, indicating a dysregulation of dopaminergic transmission (07). A meta-analysis examining resting-state fMRI in individuals at a clinically high risk of psychosis, including first-degree relatives or those with mild psychotic symptoms revealed significant hypoconnectivity, suggested that large-scale network dysfunction underlies the cognitive and perceptual disturbances in patients with schizophrenia (13).

Deficits in social cognition may be related to differential brain activation in schizophrenia as compared to health controls. A meta-analysis of existing neuroimaging data examining the neural correlates that underlie theory of mind and empathy demonstrated decreased right ventrolateral prefrontal cortical brain activation in tasks involving emotional attribution and reduced left posterior temporo-parietal junction in intention/belief attribution tasks, suggesting a role for these regions in verbal auditory hallucinations and patterns of attributions (59).

The basis for these brain abnormalities may either lie in abnormal development, degeneration of neurons after development, or both. Many subtle cognitive, motor, and behavioral changes are seen years before illness onset (24). Some developmental genes—including those identified as schizophrenia susceptibility genes—influence brain development at sequential stages, as reported from postmortem human brain and developmental animal studies (12). MRI studies suggest that the ventricular enlargement is not progressive, indicating an apparently static lesion of the brain. There is no evidence of an ongoing degenerative process, as would be indicated by reactive gliosis.

The most convincing etiologic theories postulate that a polygenetically determined disturbance of synaptic neurotransmission leads to the destruction of neuronal circuits. It has been proposed that deficits of glial growth factors resulting in disturbed neurogenesis, migration, and cell differentiation lead to glial depletion and, thus, to reduced synaptic stability (39). From a molecular genetic point of view, it has been hypothesized that single nucleotide polymorphisms (SNPs) in genes that modulate glutamatergic synaptic formation lead to disturbed plasticity and signal transduction. A disturbance of glutamatergic neurotransmission, therefore, might lead to reduced neuronal connectivity (18).

Differential diagnosis

The differential diagnosis for acute psychosis is broad and includes psychiatric illnesses, intoxication, and a variety of medical conditions (see Table 6). Younger patients who present with symptoms of psychosis and without comorbid medical or psychiatric symptoms or exposures are less complicated to diagnose. However, often patients present for care at middle or older age with little known medical history and no available collateral informants, and they are unable to give a cogent history. At these times, history of schizophrenia may not be known and the differential for presenting symptoms is widened.

Table 6. Differential Diagnoses for Schizophrenia

Psychiatric conditions

Medical conditions

Substance-intoxication

Psychotic disorders
• Schizoaffective disorder
• Brief psychotic disorder
• Schizophreniform disorder
• Delusional disorder
• Postpartum psychosis

Mood disorders
• Bipolar affective disorder
• Major depressive disorder

Personality disorders
• Schizoid personality disorder
• Schizotypal personality disorder
• Paranoid personality disorder
• Borderline personality disorder

Trauma and stressor-based disorders
• PTSD

Neurocognitive disorders
• Parkinson disease dementia
• Diffuse Lewy body dementia
• Vascular dementia
• Alzheimer disease

Delirium

Catatonia second to general medical condition

Viral encephalitis

Autoimmune encephalitides
• NMDA receptor encephalitis

Endocrine conditions
• NNMDA receptor encephalitis
• Hyperthyroidism
• Adrenal disease

Seizures

Vasculitis

Neurosarcoidosis

Wilson disease

Exogenous steroid hormones

Dopamine agonists

Synthetic cannabinoids

Stimulants
• Amphetamines
• Cocaine

Mixed stimulants or hallucinogens
• MDMA
• Cathinones (“bath salts”

Hallucinogens
• LSD
• Phencyclidine

Psychotic symptoms, such as delusions or hallucinations, are present in a variety of psychiatric disorders, such as severe unipolar and bipolar affective disorders. However, in these disorders, the affective symptoms are prominent, and there are no psychotic symptoms in the absence of mood symptoms. Psychotic symptoms are typically mood-congruent.

In schizoaffective disorder, symptoms of a major mood episode co-occur with schizophrenia criterion A (two or more positive or negative symptoms). However, criterion A symptoms must also be met and present for at least 2 weeks without the main criteria for mood disorder.

Brief psychotic disorder includes psychotic symptoms for greater than 1 day, but less than a month with return to normal functioning. Because the time course of schizophrenia requires symptoms for greater than 6 months, patients with symptoms greater than a month, but less than 6 months, are diagnosed with schizophreniform disorder, which often persists and is amended to schizophrenia with continued illness.

Schizotypal personality disorder is characterized by eccentric behavior and anomalous thought content, without other main symptoms such as hallucinations or delusions. Delusional disorder is defined by a fixed false belief or beliefs that persist greater than a month, without meeting criterion A. The condition may have functional impact regarding the specific delusions, but the patient is otherwise without impaired.

Trauma-based disorders, such as posttraumatic stress disorder (PTSD) and borderline personality disorder, can demonstrate paranoia and hallucinations stemming from exposures to dangerous situations and may be a manifestation of severe hypervigilance.

Certain dementing illnesses, such as synucleinopathies (diffuse Lewy body dementia and Parkinson dementia), Alzheimer disease, and occasionally, vascular disease, can have psychotic symptoms.

Medical causes of psychosis are also varied. Intoxication with hallucinogens, stimulants, and even alcohol can lead to psychotic symptoms. GABAergic withdrawal can result in hallucinations and delusions. Delirium, which is a waxing and waning attention caused by an underlying metabolic, pharmacologic, infectious, or inflammatory process, can also display psychotic symptoms. Other conditions, including idiopathic and iatrogenic hormonal imbalance, seizures, systemic autoimmune diseases such as lupus or autoimmune and other encephalitides, and paraneoplastic syndromes might mimic an acute psychosis with hallucinations, delusional thinking, agitation, and anxiety. However, in these cases, a medical factor will be identified with thorough physical examination, urine drug screening, laboratory blood analysis, imaging, and EEG.

Management

Adequate pharmacological treatment is the first line of treatment strategy and represents the basis of all subsequent social and psychotherapeutic interventions. Because longer duration of untreated illness is associated with greater treatment resistance, more severe positive and negative symptoms, and worse functional outcome (44), psychopharmacological treatment should be implemented as early as possible.

The disability of schizophrenia both in acute and long-term phases can be considerable. Self-neglect, apathy, and disability derived from negative symptoms and cognitive dysfunction require social care and support as a central part of services. Community mental health teams and assertive community teams as well as rehabilitation teams provide important support to vulnerable individuals. Early intervention teams focus specifically on new-onset psychosis and reducing its impact biologically, psychologically, and socially (08).

Most medications used to treat schizophrenia are dopamine receptor type 2 (D2) receptor antagonists (antipsychotics or “neuroleptics”). Although the precise mechanism of action that accounts for the effects of antipsychotic medications is still unknown, it is thought that the reduction of dopamine in the mesolimbic dopamine pathway accounts for amelioration of positive symptoms.

There are two main categories of antipsychotics, the older “typical” antipsychotics and the newer “atypical” antipsychotics. Typical antipsychotics were first developed in the 1950s and are efficacious at reducing the positive symptoms of schizophrenia but have minimal effects on negative symptoms. Traditional antipsychotics are further subdivided by their potency (amount needed for effect) and are described as low, mid, and high potency. Low-potency antipsychotics (eg, chlorpromazine) also tend to block muscarinic cholinergic receptors, leading to anticholinergic side effects (sedation, dry mouth, weight gain), whereas high-potency antipsychotics (haloperidol, fluphenazine) are more likely to produce extrapyramidal effects such as parkinsonism, acute dystonia, and akathisia. Dystonia and parkinsonism can be ameliorated by adding an anticholinergic agent such as benztropine or trihexyphenidyl. Akathisia can be treated with a beta blocker or low-dose benzodiazepine if not contraindicated.

Most side effects of conventional antipsychotics are reversible on discontinuation. Tardive dyskinesia is one consequence of antipsychotic use that may become permanent and difficult to treat. Tardive dyskinesia often manifests as involuntary disfiguring oral-buccal, upper extremity, or truncal choreiform movements. These movements may go unnoticed by the patient. Vesicular monoamine transporter inhibitors (VMAT2), such as valbenazine and deutetrabenazine, have been developed to address the effects of tardive dyskinesia by depleting presynaptic dopamine (41).

Typical antipsychotics are effective at treating positive symptoms of schizophrenia. However, they block D2 receptors globally, including in the nigrostriatal pathway (causing extrapyramidal effects), the tuberoinfundibular pathway, leading to prolactinemia, resultant decreased libido and galactorrhea, as well as the mesocortical dopamine pathway, blunting cognition, which already may be impaired by the primary schizophrenic process.

Other neurotransmitters implicated in schizophrenia include serotonin and glutamate. The second generation, or atypical antipsychotics, have action on serotonergic receptors with blockade of the serotonin 2A (5HT2A) receptors. Atypical antipsychotics seem to have more impact on negative symptoms of schizophrenia as compared to typical antipsychotics. Blocking serotonin in the mesocortical dopamine pathway may reciprocally enhance dopamine release in the prefrontal cortex, thereby improving cognition.

The first atypical antipsychotic, clozapine, was discovered in the 1950s but was not introduced clinically for 2 decades. Clozapine is the most efficacious antipsychotic; however, its use is limited by life-threatening agranulocytosis, as well as toxic megacolon. Hoping to replicate the efficacy of clozapine, olanzapine, risperidone, and quetiapine were introduced into the market in the 1990s. Aripiprazole, lurasidone, ziprasidone, paliperidone, iloperidone amongst others, have been approved for the treatment of schizophrenia. Atypical antipsychotics are considered as first-line treatment for schizophrenia and are gradually replacing typical antipsychotics in frequency of use. In contrast to first-generation antipsychotics, treatment with atypical antipsychotics increases the risk of weight gain and metabolic syndrome (33). Less common side effects of include agranulocytosis, orthostatic hypotension, and some extrapyramidal side effects.

The advent of atypical antipsychotics was heralded with the hope that these medications would be superior to conventional antipsychotics both in terms of efficacy and side effect profile. Atypical antipsychotics do have some advantages over traditional antipsychotics including fewer anticholinergic and extrapyramidal side effects, as well as improvement in negative symptoms.

Unfortunately, despite the reduction (but not elimination) of extrapyramidal effects and tardive dyskinesia risk, atypical antipsychotics can have unfavorable metabolic alterations such as dyslipidemia, glucose level increases, altered insulin receptivity, body weight gain, and worsening cardiovascular risk profile. A meta-analysis of the comparative impact of antipsychotics on metabolic function revealed that greater increases in glucose were found in males and those with higher baseline weight (45). Increased total cholesterol was associated with nonwhite ethnicity. Of the antipsychotics examined, the worst offenders were olanzapine and clozapine, in contrast to aripiprazole, brexpiprazole, cariprazine, lurasidone, and ziprasidone, as conferring the least metabolic derangements (45). Adjunctive metformin may be helpful in reducing metabolic parameters including weight, fasting glucose, and total cholesterol, though the impact on low-density lipoprotein cholesterol may not be significant (22). Patients who were metabolically normal prior to antipsychotic administration typically had greater metabolic effects, suggesting that baseline characteristics may not mitigate the risk of metabolic side effects (63).

A meta-analysis of 52 randomized trials (pooled responses of 12,649 patients on antipsychotic medication), comparing those on atypical antipsychotics (amisulpride, clozapine, olanzapine, quetiapine, risperidone, and sertindole) with those on typical antipsychotics (haloperidol and chlorpromazine) did not demonstrate superiority of atypical as compared to typical antipsychotics (16). Although drug-induced movement disorders have dramatically declined with widespread use of second-generation antipsychotics, the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial highlights that the advantages of second-generation antipsychotics in significantly reducing extrapyramidal side effects compared with haloperidol may be diminished when compared with modest doses of lower-potency first-generation drugs (09).

The differential effects on quality of life, adverse effects, sufferer satisfaction, and cost of care between typical and atypical antipsychotics might be smaller than expected (23). All antipsychotics can produce side-effect profiles that can undermine compliance and care, especially in an individual who already could be skeptical of the diagnosis. In a long-term ambulant setting, noncompliance rates of 64% to 82% with respect to discontinuation of classical and atypical antipsychotic medication have been reported (see Table 7) (34).

When symptoms are refractory to treatment, one can consider an antipsychotic with a different receptor binding profile. After treatment failures with typical and atypical agents, clozapine should be considered. Most clinicians do not use clozapine as a first-line agent due to the rare but significant adverse effects, including agranulocytosis, reduced seizure threshold, toxic megacolon, and myocarditis with the potential of death. Treatment is guided by a registry and requires frequent blood draws for medication dispensation (weekly for the first 18 months of treatment, then monthly). Clozapine should be withdrawn whenever the neutrophil count falls to less than 500 per ml. Informed consent of the patient is a prerequisite for the treatment. Despite the risks, the impressive efficacy with lack of extrapyramidal effects and dyskinesia as compared to all other antipsychotics renders it one of the most useful antipsychotics in refractory cases. Newer data suggest that the benefits of clozapine may outweigh the risks. In refractory individuals, that rate of all-cause mortality is higher for patients not receiving clozapine as compared to those on clozapine (hazard ratio 1.88) that was driven by an increase compliance. Patients on clozapine also demonstrated less self-harm than other patients (60). The benefit of clozapine may be related to continuous use, with benefits seen at a median of 6.7 years (58).

Another strategy to target negative symptoms has been the addition of an augmenting agent. Varenicline, modafinil, and dopamine enhancers, such as agonists and stimulants, have not been shown effective in improving cognitive function in schizophrenia. There are promising data suggesting improvement in cognition with the NMDA-receptor antagonist, memantine augmentation (64). In severe cases, two antipsychotics may be combined. Although monotherapy has been primarily recommended, there is emerging evidence for increased efficacy and tolerability of antipsychotic polypharmacy, with the best evidence for the combination of clozapine and aripiprazole (04).

Due to the risks of tardive dyskinesia and parkinsonism with conventional antipsychotics, researchers are pursuing compounds directed at other transmitter systems with little to no activity at dopamine receptors. Compounds target the 5HT-2A receptor (pimavanserin) as well as impact muscarinic transmission, such as xanomeline-trospium, a muscarinic-1 and -4 receptor agonist combined with a peripherally restricted muscarinic antagonist to mitigate systemic adverse reactions (25). This combination was effective in reducing positive and negative symptoms of schizophrenia in a double-blinded placebo-controlled trial; common side effects include anticholinergic effects, such as constipation, nausea, and dyspepsia.

After the first psychotic episode, medication should be continued for at least a year. A 10-year follow-up study of a randomized controlled trial of first-episode patients with full symptom reduction after a year of treatment examined the long-term consequences of discontinuing antipsychotic medication (21). A poor outcome was more likely in the discontinuation group (risk ratio of 1.84; confidence interval 1.15-2.96) with a recommendation to continue an antipsychotic for at least 3 years after the first episode. Stable patients should be maintained on the lowest possible effective dosage of medication. Subsequent episodes of psychosis likely prognosticate needing to be on medication indefinitely; however, dose reductions can be attempted after prolonged periods of stability and under close observation.

There have been attempts to target patients at risk for psychosis or after their first psychotic episode with agents either to target progression to psychosis or ameliorate severity of illness. Initial studies of omega-3 fatty acids in at-risk individuals demonstrated encouraging results in reducing transition to psychosis or maintaining cortical integrity; however, this has not been borne out in larger studies. A systematic review of adjunctive nutrients in first-episode psychosis suggests that taurine and n-acetyl cysteine may reduce symptom burden, possibly through antioxidant mechanisms (15). Participation in services targeted at phase-specific treatment of the first episode, known as early psychosis intervention, may improve mortality rates and improve outcomes (02). Further research is needed in this area.

Patients who are nonadherent to oral medication should be offered a depot application (long-acting injectable form) of medication. Depot applications are available for the typical antipsychotics (fluphenazine, haloperidol) and for some atypical antipsychotics (risperidone, olanzapine, paliperidone, and aripiprazole). An examination of long-acting injectable paliperidone in recent-onset schizophrenia demonstrated decreased hospitalization and reduced total healthcare dollars, suggesting this strategy may be considered prior to evidence of nonadherence (05). A meta-analysis of effectiveness and efficacy trials of antipsychotics suggest that long-acting injectables perform better in the real world than indicated is in randomized controlled trials, further reinforcing their use in patients who are willing to take them (14).

Another accepted and well-tolerated option in treatment-refractory illness and in acute catatonic schizophrenia is electroconvulsive therapy, the induction of a seizure through external applications of electrodes under general anesthesia. Typically, patients undergo an index course of three treatments per week for 6 to 12 treatments (or until symptom remission) and may include periodic maintenance treatments to prevent recurrence. Common side effects are headache and paroxysmal decrease of short-term memory, which typically recover after terminating therapy (06). There are some cases of persistent changes in both retrograde and anterograde memory. Although prospective, controlled data are limited, the side effects profile of electroconvulsive therapy in combination with antipsychotics does not differ from that seen under antipsychotics alone. A randomized, double-blinded, sham-controlled study of repetitive transcranial magnetic stimulation (rTMS) using high-frequency stimulation over the left dorsolateral prefrontal cortex improved negative symptoms as compared to the control group (31).

Table 7. Dosage and Side Effect Profile of Different Antipsychotic Regimens for Treating Schizophrenia

Drug	Typical dosage	Side effect profile
Aripiprazole:	15 to 30 mg (no titration required)	Akathisia, restlessness, sleeplessness, headache, dizziness. Less common for aripiprazole to cause weight gain or metabolic syndrome; it also has a different mechanism of action compared to other atypicals. Least likely to cause QTc prolongation. Comes in a long-acting injectable form. Can reduce prolactin that can be elevated by other antipsychotics (26). Can cause compulsive behaviors.
Asenapine:	10 to 20 mg per day in two doses (sublingual route)	Restlessness, disturbed sleep, altered touch sensation, seizures. Metabolically appears neutral. Lesser potential for weight gain and hyperprolactinemia compared to risperidone. Not bioavailable if swallowed. Complicated administration.
Brexpiprazole:	1 to 4 mg per day	Gastrointestinal symptoms, akathisia, compulsive behaviors
Cariprazine:	3 to 9 mg per day	Risks of akathisia, extrapyramidal symptoms, metabolically neutral
Clozapine:	400 to 600 mg per day	Best medication in patients with tardive dyskinesia and parkinsonism with least extrapyramidal effects. Leukopenia, agranulocytosis (1% to 2%), lowering of seizure threshold, sedation, anticholinergic effects, hypersalivation, weight gain, arrhythmia, myocarditis, cardiomyopathy, toxic megacolon
Iloperidone:	4 to 24 mg per day	Insomnia, weight gain, diarrhea, tachycardia, QTc prolongation
Lumateperone:	42 mg per day	Advertised as “titration free.” Sedation, dry mouth
Lurasidone:	40 to 120 mg per day (with food)	Somnolence, akathisia, nausea
Olanzapine:	10 to 20 mg per day	Sedation, dizziness, orthostatic hypotension, increased appetite, metabolic syndrome, anticholinergic effects, extrapyramidal effects. Comes in a long-acting injectable form.
Quetiapine:	600 to 800 mg per day	Sedation, dizziness, orthostatic hypotension, increased appetite, weight gain, anticholinergic effects, transient increase of liver enzymes. Can cause QTc prolongation. Less extrapyramidal effects compared to other atypicals.
Risperidone:	6 to 8 mg per day	Extrapyramidal effects, hyperprolactinemia, restlessness, sleeplessness, headache, dizziness, orthostatic hypotension, tachycardia. Comes in a long-acting injectable form.
Ziprasidone:	2x 80 mg per day (no titration required)	QTc prolongation, dizziness, asthenia, headache, thirst, anticholinergic effects, dyspepsia, exanthema, urinary incontinence
Adapted from (54)

Neuroleptic malignant syndrome is a rare but lethal consequence of antipsychotic administration and is characterized by rigidity, hyperthermia, confusion, diaphoresis, autonomic instability, and lab abnormalities including leukocytosis and elevated creatine phosphokinase. It is critical that neuroleptic malignant syndrome is recognized. Treatment includes the discontinuation of the offending agent and supportive care. Agents such as the skeletal muscle relaxant, dantrolene, or dopamine agonists like bromocriptine, can be tried adjuncts. Antipsychotics should be avoided for a few weeks after resolution of the episode; however, due to the nature of schizophrenia, it is unlikely that they can be permanently avoided.

Along with the acute treatment and intervention strategies, patients should be offered psychoeducation, occupational therapy, cognitive therapy, and other methods to regain structure of their daily activities. Patients should urgently be advised not to consume any recreational drugs. Psychotherapeutic interventions frequently focus on helping patients identify and achieve their personal goals while coping with the disease. Although, employment rates are low among the severely mentally ill, there is evidence that supported employment in a cohort of clients with first-episode psychosis was an independent predictor of vocational recovery in the following 12 months (37). Cognitive, behaviorally oriented service seemed to be beneficial in reducing early negative symptom exacerbations when compared to treatment as usual (27).

Although medication and electroconvulsive therapy are the primary treatment modalities for schizophrenia, there is increasing interest in using novel cognitive training approaches. Cognitive symptoms are generally more difficult to target with pharmacotherapy. Neuroscience-informed cognitive remediation can occur remotely, which has implications for the ability to distribute the technology. Auditory processing training for 40 hours, as compared to video game controls, demonstrated improved global cognition and problem-solving ability and a decrease in positive symptoms (35). The improvements were found to be sustained at a 6-month assessment. Patients engaged in 20 or 40 hours of auditory or visual training demonstrated improved emotion processing and social cognition, though symptoms were unchanged (48). Atlhough these computer-based treatments have the advantage of being free of metabolic and extrapyramidal side effects, they do require effort and motivation to complete, which may limit their use.

For the prodrome of schizophrenia following interventions are considered appropriate:

• Careful observation
• Consideration of differential diagnosis, including organic causes
• Consideration of comorbidity, such as substance abuse
• Aim to minimize risk of relapse
• Aim to eliminate exposure to cannabis and psychostimulants via psychoeducation, stress management, and maintenance antipsychotic treatment
• Discussion of treatment options, such as commencement of antipsychotics and CBT

Outcomes

A Cochrane review of 75 randomized controlled trials concluded that maintenance treatment with an antipsychotic significantly prevented relapse as compared to placebo for up to 2 years of follow-up, with a trend toward increased quality of life. However, antipsychotics as a group were associated with an increased risk of adverse effects, including extrapyramidal symptoms and metabolic changes (10).

Patients with schizophrenia die an estimated 10 or more years earlier than the life expectancy of nonaffected patients. Suicide is a major cause of death, but the gap is also likely multifactorial. As compared to controls, a meta-analysis revealed that patients with schizophrenia are at increased risk of stroke and stroke-related complications, including mortality, suggesting interventions for primary prevention and mitigation of neurovascular risk factors (11).

Special considerations

Pregnancy

Generally, the use of psychotropic medication during pregnancy is indicated when risk to the fetus from exposure to medication is outweighed by the risk of untreated psychosis in the mother. Data from large health surveys indicate that antipsychotic medication confers no or only small risk for organic malformation. Findings in the published literature on the safety of antipsychotic medication are limited but encouraging (55). For atypical antipsychotics, a study of the effects of different atypical antipsychotics on rates of major malformation, spontaneous abortion, and stillbirth, as well as birth weight and gestational age at birth, did not reveal significant differences between mentally ill women who were treated with atypical medication versus mentally healthy women in any of the outcomes, except a higher rate of low birth weight in the offspring of women on medication (38). Continuation of olanzapine and quetiapine in pregnancy are associated with increased risk of gestational diabetes, as compared to those who discontinued use. This is likely related to the known metabolic side effects of these drugs (43). Given the lack of controlled, prospective studies, the clinician needs to weigh the substantial risk of untreated psychosis with the potential risk of the medication.

Anesthesia

Patients with schizophrenia may have a higher risk of developing cardiovascular disease, often suffer from silent cardiovascular infarction, show increased sensitivity to the hypotensive effects of anesthesia due to antipsychotic medication, and may be less sensitive to postoperative abdominal pain (28). The latter is especially important because postoperative paralytic ileus is a serious side effect frequently encountered in schizophrenic patients (29). There are only limited data on continuation of antipsychotic medication preoperatively, but patients who discontinued antipsychotic medication preoperatively, significantly more frequently suffered from postoperative confusion as compared to patients who continued their medication (30), whereas frequency of intraoperative hypotension and arrhythmia did not differ between groups. It is recommended to continue antipsychotic medication perioperatively.

References

01: American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th edition. Washington, DC: American Psychiatric Association, 2013.
02: Anderson KK, Norman R, MacDougall A, et al. Effectiveness of early psychosis intervention: comparison of service users and nonusers in population-based health administrative data. Am J Psychiatry 2018;175(5):443-52. PMID 29495897
03: Ayano G, Tesfaw G, Shumet S. The prevalence of schizophrenia and other psychotic disorders among homeless people: a systematic review and meta-analysis. BMC Psychiatry 2019;19(1):370. PMID 31775786
04: Azorin FM, Simon N. Antipsychotic polypharmacy in schizophrenia: evolving evidence and rationale. Expert Opin Drug Metab Toxicol 2020;16(12):1175-86. PMID 32930009
05: Basu A, Benson C, Turkoz I, Patel C, Baker P, Brown B. Health care resource utilization and costs in patients receiving long-acting injectable vs oral antipsychotics: a comparative analysis from the Disease Recovery Evaluation and Modification (DREaM) study. J Manag Care Spec Pharm 2022;28:1086-95. PMID 36125055
06: Braga RJ, Petrides G. The combined use of electroconvulsive therapy and antipsychotics in patients with schizophrenia. J ECT 2005;21(2):75-83. PMID 15905747
07: Breier A, Su TP, Saunders R, et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci U S A 1997;94(6):2569-74. PMID 9122236
08: Burns T. Modern community care strategies for schizophrenia care: impacts on outcome. In: Gattaz WF, Busatto G, editors. Advances in Schizophrenia Research 2009. New York: Springer, 2010:417-27.
09: Caroff SN, Hurford I, Lybrand J, Campbell EC .Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial. Neurol Clin 2011;29:127-48. PMID 21172575
10: Ceraso A, Lin JJ, Schneider-Thoma, et al. Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev 2020;8:CD008016. PMID 32840872
11: Chu RST, Chong RCH, Chang DHH, et al. The risk of stroke and post-stroke mortality in people with schizophrenia: a systematic review and meta-analysis study. Psychiatry Res 2024;332:115713. PMID 38183926
12: Corfas G, Roy K, Buxbaum JD. Neuregulin 1-erbB signaling and the molecular/cellular basis of schizophrenia. Nat Neurosci 2004;7(6):575-80. PMID 15162166
13: Del Fabro L, Schmidt A, Fortea L, et al. Functional brain network dysfunction in subjects at high-risk for psychosis: a meta-analysis of resting-state functional connectivity. Neurosci Biobehav Rev 2021;128:90-101. PMID 34119524
14: Efthimiou O, Taipale H, Radua J, et al. Efficacy and effectiveness of antipsychotics in schizophrenia: network meta-analyses combining evidence from randomised controlled trials and real-world data. Lancet Psychiatry 2024;11:102-11. PMID 38215784
15: Firth J, Rosenbaum S, Ward PB, et al. Adjunctive nutrients in first-episode psychosis: a systematic review of efficacy, tolerability, and neurobiological mechanisms. Early Interv Psychiatry 2018;12(5):774-83. PMID 29564167
16: Geddes J, Freemantle N, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta regression analysis. BMJ 2000;321:1371-6. PMID 11099280
17: Gottesman II. Schizophrenia genesis: The origins of madness. New York, NY: W H Freeman and Co, 1991.
18: Harrison PJ, Owen MJ. Genes for schizophrenia. Recent findings and their pathophysiological implications. Lancet 2003;361(9355):417-9. PMID 12573388
19: Harrison PJ, Weinberger DA. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 2005;10(1):40-68. PMID 15263907
20: Heinz A, Braus DF, Romero B, et al. Genetic and psychopharmacological effects on prefrontal cortical function in schizophrenia. Nervenarzt 2004;75(9);845-56. PMID 15372159
21: Hui CLM, Honer WG, Lee EHM, et al. Long-term effects of discontinuation from antipsychotic maintenance following first-episode schizophrenia and related disorders: a 10 year follow-up of a randomized double-blind trial. Lancet Psychiatry 2018;5(5):432-42. PMID 29551618
22: Jiang WL, Cai DB, Zhang L, et al. Adjunctive metformin for antipsychotic-induced dyslipidemia: a meta-analysis of randomized, double-blind placebo-controlled trials. Transl Psychiatry 2020;10(1):117. PMID 32327628
23: Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006;63:1079-87. PMID 17015810
24: Jones P, Rodgers B, Murray R, Marmot M. Child development risk factors for adult schizophrenia in the British 1946 birth cohort. Lancet 1994;344(8934):1398-1402. PMID 7968076
25: Kaul I, Sawchak S, Correll CU, et al. Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial. Lancet 2024;403(10422):160-70. PMID 38104575
26: Kelly DL, Powell MM, Wehring HJ. Adjunct aripiprazole reduces prolactin and prolactin-related adverse effects in premenopausal women with psychosis: results from the DAAMSEL clinical trial. J Clin Psychopharmacol 2018;38(4):317-26. PMID 29912799
27: Klingberg S, Wittorf A, Fischer A, Jakob-Deters K, Buchkremer G, Wiedemann G. Evaluation of a cognitive behaviourally oriented service for relapse prevention in schizophrenia. Acta Psychiatr Scand 2010;121(5):340-50. PMID 19895624
28: Kudoh A. Perioperative management for chronic schizophrenic patients. Anesth Analg 2005;101(6):1867-72. PMID 16301276
29: Kudoh A, Ishihara H, Matsuki A. Pituitary-adrenal and parasympathetic function in chronic schizophrenic patients with postoperative ileus or hypotension. Neuropsychobiology 1999;39(3):125-30. PMID 25549482
30: Kudoh A, Katagai H, Takase H, Takazawa T. Effect pf preoperative discontinuation of antipsychotics in schizophrenic patients on outcome during and after anesthesia. Eur J Anaesthesiol 2004;21(5):414-6. PMID 15141803
31: Kumar N, Vishnubhatla S, Wadhawan AN, Minhas S, Gupta P. A randomized, doublt blind, sham-controlled trial of repetitive transcranial magnetic stimulation (rTMS) in the treatment of negative symptoms of schizophrenia. Brain Stimul 2020;13(3):840-9. PMID 32289715
32: Lawrie SM, Buechel C, Whalley HC, Frith CD, Friston KJ, Johnstone EC. Reduced frontotemporal functional connectivity in schizophrenia associated with auditory hallucinations. Biol Psychiatry 2002;51(12):1008-11. PMID 12062886
33: Liao CH, Chang CS, Wei WC, et al. Schizophrenia patients at higher risk of diabetes, hypertension and hyperlipidaemia: a population based study. Schizophr Res 2011;126:110-6. PMID 21216567
34: Lieberman JA, Stroup TS, McEvoy JP, et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23. PMID 16172203
35: Loewy R, Fisher M, Ma S, et al. Durable cognitive gains and symptom improvement are observed in individuals with recent-onset schizophrenia 6 months after a randomized trial of auditory training completed remotely. Schizophr Bull 2022;48(1):262-72. PMID 34510196
36: Lu L, Dong M, Zhang L, et al. Prevalence of suicide attempts in individuals with schizophrenia: a meta-analysis of observational studies. Epidemiol Psychiatr Sci 2019:29:e39. PMID 31172899
37: Major BS, Hinton MF, Flint A, Chalmers-Brown A, McLoughlin K, Johnson S. Evidence of the effectiveness of a specialist vocational intervention following first episode psychosis: a naturalistic prospective cohort study. Soc Psychiatry Psychiatr Epidemiol 2010;45(1):1-8. PMID 19305936
38: McKenna K, Koren G, Tetelbaum M, et al. Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. J Clin Psychiatry 2005;66(4):444-9; quiz 546. PMID 15816786
39: Moises HW, Zoega T, Gottesmann II. The glial growth factors deficiency and synaptic destabilization hypothesis of schizophrenia. BMC Psychiatry 2002;2:8. PMID 12095426
40: Mulligan LD, Varese F, Harris K, Haddock G. Alcohol use and suicide-related outcomes in people with a diagnosis of schizophrenia: a comprehensive systematic review and meta-analysis. Psychol Med 2024;54(1):1-12. PMID 37818642
41: Niemann N, Jankovic J. Treatment of tardive dyskinesia: a general overview with focus on the vesicular monoamine transporter 2 inhibitors. Drugs 2018;78(5):525-41. PMID 29524074
42: Nordentoft M, Jeppesen P, Abel M, et al. OPUS study: suicidal behavior, suicidal ideation and hopelessness among patients with first episode psychosis. One-year-follow-up of a randomised controlled trial. Br J Psychiatry Suppl 2002;43:s98-106. PMID 12271808
43: Park Y, Hernandez-Diaz S, Bateman BT, et al. Continuation of atypical antipsychotic medication during early pregnancy and the risk of gestational diabetes. Am J Psychiatry 2018;175(6):564-74. PMID 29730938
44: Perkins DO, Gu H, Boteva K, Lieberman JA. Relationship between duration of untreated psychosis and outcome in first episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry 2005;162(10):1785-804. PMID 16199825
45: Pillinger T, McCutcheon RA, Vano L, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry 2020;7(1):64-77. PMID 31860457
46: Puri BK, Hall A, Ho R, et al. Revision notes in psychiatry. 3rd edition. Boca Raton, FL: CRC Press, 2014.
47: Saito Y, Sakurai H, Kane JM, et al. Predicting relapse with residual symptoms in schizophrenia: a secondary analysis of the PROACTIVE trial. Schizophr Res 2020;215:173-80. PMID 31672387
48: Scoriels L, Genaro LT, Keffer S, et al. Changes in emotion processing and social cognition with auditory versus visual neuroscience-informed cognitive training in individuals with schizophrenia. Schizophr Res 2022;241:267-74. PMID 35182906
49: Semple DM, McIntosh AM, Lawrie SM. Cannabis as a risk factor for psychosis: systematic review. J Psychopharmacol 2005;19(2):187-94. PMID 15871146
50: Spoletini I, Piras F, Fagioli S, et al. Suicidal attempts and increased and increased right amygdala volume in schizophrenia. Schizophr Res 2011;125:30-40. PMID 20869847
51: Starzer MSK, Hansen HG, Hjorthøj C, Speyer H, Albert N, Nordentoft M. Predictors of mortality following a schizophrenia spectrum diagnosis: evidence from the 20-year follow-up of the OPUS randomized controlled trial. Schizophr Bull 2023;49(5):1256-68. PMID 37527479
52: Sun S, Xiao S, Guo Z, et al. Meta-analysis of cortical thickness reduction in adult schizophrenia. J Psychiatry Neurosci 2023;48(6):E461-70. PMID 38123240
53: Tandon R, Jibson MD. Suicidal behavior in schizophrenia: diagnosis, neurobiology and treatment implications. Curr Opin Psychiatry 2003;16(2):193-7.
54: Taylor D, Paton C, Kapur S. The Maudsley Prescribing Guidelines in Psychiatry. 11th edition. Wiley-Blackwell: West Sussex, UK, 2012:11-21.
55: Trixler M, Gati A, Fekete S, Tenyi T. Use of antipsychotics in the management of schizophrenia during pregnancy. Drugs 2005;65(9):1193-206. PMID 15916447
56: van Os J, Kapur S. Schizophrenia. Lancet 2009;374:635-45. PMID 19700006
57: Veen ND, Selten JP, van der Tweel I, Feller WG, Hoek HW, Kahn RS. Cannabis use and age at onset of schizophrenia. Am J Psychiatry 2004;161(3):501-6. PMID 14992976
58: Vermeulen JM, van Rooijen G, van de Kerkhof MPJ, et al. Clozapine and long-term mortality risk in patients with schizophrenia: a systematic review and meta-analysis of studies lasting 1.1-12.5 years. Schizophr Bull 2019;45(2):315-29. PMID 29697804
59: Vucurovic K, Cillies S, Kaladjian A. Neural correlates of theory of mind and empathy in schizophrenia: an activation likelihood estimation meta-analysis. J Psychiatr Res 2020;120:163-74. PMID 31689587
60: Wimberly T, MacCabe JH, Laursen TM, et al. Mortality and self-harm in association with clozapine in treatment-resistant schizophrenia. Am J Psychiatry 2017;174(10):990-8.** PMID 28750580
61: Wright IC, Rabe-Hesketh S, Woodruff PW, David AS, Murray RM, Bullmore ET. Meta-analysis of regional brain volumes in schizophrenia. Am J Psychiatry 2000;157:16-25. PMID 10618008
62: Yung AR, McGorry PD. The initial prodrome in psychosis: descriptive and qualitive aspects. Aust N Z J Psychiatry 1996;30(5):587-99. PMID 8902166
63: Zhang Y, Wang Q, Reynolds GP, et al. Metabolic effects of 7 antipsychotics on patients with schizophrenia: a short-term, randomized, open-label multicenter, pharmacologic trial. J Clin Psychiatry 2020;81(3):19m12785. PMID 32237292
64: Zheng W, Zhu XM, Zhang Q, et al. Adjunctive memantine for major mental disorders: A systematic review and meta-analysis of randomized double-blind controlled trials. Schizophr Res 2019;209:12-21. PMID 311664254

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Author

Rebekah Jakel MD PhD

Dr. Jakel of Duke University has no relevant financial relationships to disclose.
See Profile

Editor

Victor W Mark MD

Dr. Mark of the University of Alabama at Birmingham has no relevant financial relationships to disclose.
See Profile

Former Authors

Carolin Opgen-Rhein MD
Michael Dettling MD
Claudia Murton MBBch
Rohit Shankar MRCPsych
Melvyn WB Zhang MBBS MRCPsych

Patient Profile

Age range of presentation: 13 to 44 years
Sex preponderance: Male slightly higher than female
Heredity: Heredity is a factor; however, it does not explain all expression of the disease.
Population groups selectively affected: none selectively affected
Occupation groups selectively affected: none selectively affected

ICD & OMIM codes

ICD-10: Schizophrenia: F20.9

Schizophreniform disorder: F20.81

Unspecified catatonia: F06.1
OMIM: Schizophrenia: #181500

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Schizophrenia

Differential Diagnosis

schizoaffective disorder
bipolar affective disorder with psychosis
major depressive disorder, severe with psychosis
catatonia
schizophreniform disorder
- brief psychotic disorder
- delusional disorder
- delirium
- substance intoxication
- amphetamines
- hallucinogens
- alcohol
- withdrawal
- hormonal imbalance
- dehydration
- diffuse lewy body dementia
- Alzheimer dementia
- Parkinson disease psychosis
- PTSD
- Borderline personality disorder

Also Relevant

Catatonia

Clinical Categories

Neurobehavioral & Cognitive Disorders

Patient Handouts

Schizophrenia

Web References

Guidelines

Canadian Psychiatric Association: Treatment of Schizophrenia

Clinical Trials

Testing

Schizophrenia

Schizophrenia

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Table 1. Diagnostic Criteria for Schizophrenia, as defined by the Diagnostic and Statistical Manual of Mental Disorders, 5th edition

Table 2. Common Types of Delusions

Table 3. Features of Disorganization Noted in Speech in Schizophrenia

Table 4. Prodrome of Schizophrenia

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Table 5. The Common Risk Factors for Schizophrenia

Epidemiology

Prevention

Differential diagnosis

Table 6. Differential Diagnoses for Schizophrenia

Diagnostic workup

Management

Table 7. Dosage and Side Effect Profile of Different Antipsychotic Regimens for Treating Schizophrenia

Outcomes

Special considerations

Pregnancy

Anesthesia

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Metal neurotoxicity

Vascular cognitive impairment

Addictive disorders

Automatic-voluntary dissociation

Wilson disease

Pre-mild cognitive impairment

PART (Primary age-related tauopathy)

Anti-LGI1 encephalitis

This is an article preview.
Start a Free Account
to access the full version.